Offering a selection of packaging options and concentrations (160, 240, 300, 320 and 350), OptiMARK (gadoversetamide injection) is one of the first MRI contrast agent approved for use with power injection. Using OptiMARK with the OptiStar LE power injector at rates of 1 to 2 ml per second image quality, diagnostic accuracy, reproducibility, accurate timing of bolus and a tight bolus (when used with saline flush at the same flow rate as the contrast media), said Tyco. It is available in glass vials in a range of sizes or easy-to-use Ultraject prefilled syringes.
If you enjoy this content, please share it with a colleague
MRI Media Approved for Use with Power Injection
Related Content
August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...
July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...
May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...
July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...
Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...
Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...
May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...
November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...
January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...